Company Profiles

driven by the PitchBook Platform

ArisGen

2006 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Accelerator/Inc LATEST DEAL TYPE
1 INVESTORS
Description

Developer of formulation technology focused on the treatment of metabolic diseases and oncology. The company's formulation technology, ArisCrown, enables delivery of therapeutic peptides through oral, buccal or sub-lingual routes and transforms the injectable peptide market offering oral alternatives for these medications.

Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Delivery
Other Industries
Other Devices and Supplies
Biotechnology
Primary Office
  • Chemin des Aulx,14
  • 1228 Plan-les-Ouates
  • Geneva
  • Switzerland

+41 022 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ArisGen’s full profile, request a free trial.

ArisGen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 12-Jun-2014 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

ArisGen Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Swiss Startup Invest Other Minority 000 0000 000000 0

ArisGen Executive Team (3)

Name Title Board
Seat
Contact
Info
Paolo Botti Ph.D Chief Scientific Officer, Board Member and Founder
Christophe Guichard Chief Financial Officer

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »

ArisGen Board Members (3)

Name Representing Role Since Contact
Info
Jesús Martin-Garcia Self Chairman 000 0000
Paolo Botti Ph.D ArisGen Chief Scientific Officer, Board Member and Founder 000 0000

1 Former Board Member

You’re viewing 2 of 3 board members. Get the full list »